PL2440230T3 - Schematy leczenia do leczenia choroby neurologicznej - Google Patents

Schematy leczenia do leczenia choroby neurologicznej

Info

Publication number
PL2440230T3
PL2440230T3 PL10786859T PL10786859T PL2440230T3 PL 2440230 T3 PL2440230 T3 PL 2440230T3 PL 10786859 T PL10786859 T PL 10786859T PL 10786859 T PL10786859 T PL 10786859T PL 2440230 T3 PL2440230 T3 PL 2440230T3
Authority
PL
Poland
Prior art keywords
treatment
neurological disease
regimes
treatment regimes
neurological
Prior art date
Application number
PL10786859T
Other languages
English (en)
Inventor
Michael Tymianski
Jonathan David Garman
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of PL2440230T3 publication Critical patent/PL2440230T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
PL10786859T 2009-06-10 2010-06-10 Schematy leczenia do leczenia choroby neurologicznej PL2440230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18598909P 2009-06-10 2009-06-10
EP10786859.8A EP2440230B1 (en) 2009-06-10 2010-06-10 Treatment regimes for treatment of neurological disease
PCT/US2010/038200 WO2010144721A2 (en) 2009-06-10 2010-06-10 Model systems and treatment regimes for treatment of neurological disease

Publications (1)

Publication Number Publication Date
PL2440230T3 true PL2440230T3 (pl) 2021-06-14

Family

ID=43309469

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10786859T PL2440230T3 (pl) 2009-06-10 2010-06-10 Schematy leczenia do leczenia choroby neurologicznej

Country Status (14)

Country Link
US (2) US8940699B2 (pl)
EP (2) EP2440230B1 (pl)
JP (2) JP6005514B2 (pl)
CN (1) CN102458441A (pl)
AU (1) AU2010258664B2 (pl)
BR (1) BRPI1010718A2 (pl)
CA (1) CA2765169C (pl)
DK (1) DK2440230T3 (pl)
ES (1) ES2847293T3 (pl)
HR (1) HRP20210112T1 (pl)
HU (1) HUE053131T2 (pl)
PL (1) PL2440230T3 (pl)
PT (1) PT2440230T (pl)
WO (1) WO2010144721A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
EP2616094B1 (en) 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
SI2723363T1 (sl) 2011-06-24 2018-12-31 Nono Inc. Kombinacijska terapija za ishemijo
MX364562B (es) * 2011-12-13 2019-04-30 Nono Inc Terapia para hemorragia subaracnoidea e isquemia.
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2013204309A1 (en) * 2012-11-13 2014-05-29 Biodiem Limited Therapeutic Compounds and Uses Thereof
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
HUE043820T2 (hu) * 2012-11-28 2019-09-30 Nono Inc Liofilizált TAT-NR2B9c készítmény
SG11201609911YA (en) * 2014-05-28 2016-12-29 Nono Inc Chloride salt of tat-nr2b9c
EP3450446A1 (en) * 2016-04-27 2019-03-06 Biocells (Beijing) Biotech Co., Ltd. Treatment method for excitatory neurotoxicity-related injury
ES2869300T3 (es) * 2016-04-27 2021-10-25 Biocells Beijing Biotech Co Ltd Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
CN110049994B (zh) * 2016-12-08 2023-05-02 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
US11767344B2 (en) 2017-07-05 2023-09-26 Biocells (Beijing) Biotech Co., Ltd. Pharmaceutically acceptable salts of polypeptides and methods of inhibiting the interaction between psd-95 and n-methyl-d-aspartic acid receptor (nmdar)
WO2019006692A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
BR112020006321A2 (pt) * 2017-09-30 2020-11-17 Biocells (Beijing) Biotech Co., Ltd. composição de peptídeos para tratamento de lesões relacionadas a neurotoxicidade excitatória
CN113121641B (zh) 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN113150065B (zh) 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
CN113735938A (zh) 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN114469084B (zh) * 2022-04-02 2022-06-24 剑博微电子(深圳)有限公司 一种基于高精度adc的血氧监测系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
EP1578365A4 (en) * 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
PL1622639T3 (pl) 2003-05-02 2013-06-28 Lundbeck H As Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu
EP2043671B1 (en) * 2006-07-11 2020-05-20 NoNO Inc. Peptide and composition thereof for use in treating stroke with fever
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
CA2679831C (en) 2007-03-02 2018-10-02 Arbor Vita Corporation Treating stroke and other diseases without inhibiting n-type calcium channels
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
ES2542522T3 (es) 2008-07-09 2015-08-06 University Of Copenhagen Péptidos modificados como inhibidores potentes de la interacción entre receptor de NMDA/PSD-95
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
SI2723363T1 (sl) 2011-06-24 2018-12-31 Nono Inc. Kombinacijska terapija za ishemijo
MX364562B (es) 2011-12-13 2019-04-30 Nono Inc Terapia para hemorragia subaracnoidea e isquemia.
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia

Also Published As

Publication number Publication date
US8940699B2 (en) 2015-01-27
EP3808366A1 (en) 2021-04-21
EP2440230B1 (en) 2020-11-11
WO2010144721A2 (en) 2010-12-16
HRP20210112T1 (hr) 2021-04-16
DK2440230T3 (da) 2021-01-18
AU2010258664A1 (en) 2012-01-12
CA2765169A1 (en) 2010-12-16
JP6005514B2 (ja) 2016-10-12
JP2012530057A (ja) 2012-11-29
CA2765169C (en) 2019-06-18
EP2440230A4 (en) 2014-05-28
HUE053131T2 (hu) 2021-06-28
US9610323B2 (en) 2017-04-04
EP2440230A2 (en) 2012-04-18
BRPI1010718A2 (pt) 2016-03-15
CN102458441A (zh) 2012-05-16
ES2847293T3 (es) 2021-08-02
US20150202253A1 (en) 2015-07-23
AU2010258664B2 (en) 2015-05-28
PT2440230T (pt) 2021-02-03
JP6220371B2 (ja) 2017-10-25
JP2016041731A (ja) 2016-03-31
US20120269733A1 (en) 2012-10-25
WO2010144721A3 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
PL2440230T3 (pl) Schematy leczenia do leczenia choroby neurologicznej
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
HK1169804A1 (zh) 治療疼痛的方法
IL219073A (en) A drug combination for cancer treatment
EP2409634A4 (en) ENDOSCOPE OF TREATMENT
GB0908193D0 (en) Treatment of disease state
EP2160100A4 (en) TREATMENT OF GRAFT REJECTION DISEASE
HK1176870A1 (zh) 疾病的治療方法
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
PL2477656T3 (pl) Leczenie stanów neurologicznych
GB0908666D0 (en) Treatment of proteostatic disease
GB0817859D0 (en) Treatment of proteostatic disease
GB0819543D0 (en) Treatment of proteostatic disease
HU0900722D0 (en) Compounds for the treatment of neurological disorders
TWM390783U (en) Improved structure of push bed for medical treatment
HUP0900504A2 (en) Cream for treatment of skin-irritation
GB0913427D0 (en) Compounds for treatment of imflammation